Entry1.31→Now1.39
Paragon spin-out Mentari migraine pipeline long Open original source
INM InMed Pharmaceuticals Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
19:00
Sep 11
Sep 11
Paragon spin-out Mentari migraine pipeline long
InMed Pharmaceuticals is set to become Mentari Therapeutics via reverse merger, trading as MTRI on Nasdaq, as the 8th company spun out of the Paragon Therapeutics ecosystem. The author argues Paragon operates as a repeatable 'biotech factory' that develops antibody programs and spins them into independent biotechs, with Apogee acquired by AbbVie and Spyre and Korsana as prior examples. Mentari's pipeline targets migraine prevention with MT-001 (anti-PACAP antibody) and MT-002 (bispecific CGRP x PACAP antibody), with ~$290M financing and catalysts of MT-002 Phase 1 in 2027 and MT-001 Phase 2a/PoC in 2028. If clinical data is compelling, Mentari could become an acquisition target for Big Pharma, though the author flags significant early-stage clinical and development risk.
HIGH
About INM Investor Commentary
Across the available history and selected sources, Buzzberg tracks INM (InMed Pharmaceuticals Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Secure-Chipmunk6112.